Michael S Rutenberg1,2, Ronny L Rotondo3, Dinesh Rao4, Adam L Holtzman5,6, Daniel J Indelicato5,6, Soon Huh5,6, Christopher G Morris6, William M Mendenhall5,6. 1. Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA. mrutenberg@floridaproton.org. 2. University of Florida Health Proton Therapy Institute, 2015 N Jefferson St, Jacksonville, FL, 32206, USA. mrutenberg@floridaproton.org. 3. Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA. 4. Department of Radiology, University of Florida College of Medicine, Jacksonville, FL, USA. 5. Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA. 6. University of Florida Health Proton Therapy Institute, 2015 N Jefferson St, Jacksonville, FL, 32206, USA.
Abstract
BACKGROUND: Craniopharyngioma is a benign tumor that commonly develops within the suprasellar region. The tumor and treatment can have debilitating consequences for pediatric and adult patients, including vision loss and pituitary/hypothalamic dysfunction. Most craniopharyngioma series focus on treatment of the pediatric population. We evaluated the outcomes of all adult craniopharyngioma patients treated at our institution using proton therapy to report outcomes for disease control, treatment-related toxicity, and tumor response. METHODS: We analyzed 14 adult patients (≥ 22 years old). All patients had gross disease at the time of radiotherapy. Five were treated for de novo disease and 9 for recurrent disease. Patients received double-scattered conformal proton therapy to a mean dose of 54 GyRBE in 1.8 GyRBE/fraction (range 52.2-54 GyRBE). Weekly magnetic resonance imaging (MRI) helped to evaluate tumor changes during radiotherapy. RESULTS: With median clinical and radiographic follow-up of 29 and 26 months, respectively, the 3-year local control and overall survival rates were both 100%. There were no grade 3 or greater acute or late radiotherapy-related side effects. There was no radiotherapy-related vision loss or optic neuropathy. No patients required intervention or treatment replanning due to tumor changes during radiotherapy. Two patients experienced transient cyst expansion at their first post-radiotherapy MRI. Both patients were followed closely clinically and radiographically and had subsequent dramatic tumor/cyst regression, requiring no interventions. CONCLUSIONS: Our data support the safety and efficacy of proton therapy in the treatment of adult craniopharyngioma as part of primary or salvage treatment. We recommend early consideration of radiotherapy. This trial was registered at www.clinicaltrials.gov as #NCT03224767.
BACKGROUND:Craniopharyngioma is a benign tumor that commonly develops within the suprasellar region. The tumor and treatment can have debilitating consequences for pediatric and adult patients, including vision loss and pituitary/hypothalamic dysfunction. Most craniopharyngioma series focus on treatment of the pediatric population. We evaluated the outcomes of all adult craniopharyngiomapatients treated at our institution using proton therapy to report outcomes for disease control, treatment-related toxicity, and tumor response. METHODS: We analyzed 14 adult patients (≥ 22 years old). All patients had gross disease at the time of radiotherapy. Five were treated for de novo disease and 9 for recurrent disease. Patients received double-scattered conformal proton therapy to a mean dose of 54 GyRBE in 1.8 GyRBE/fraction (range 52.2-54 GyRBE). Weekly magnetic resonance imaging (MRI) helped to evaluate tumor changes during radiotherapy. RESULTS: With median clinical and radiographic follow-up of 29 and 26 months, respectively, the 3-year local control and overall survival rates were both 100%. There were no grade 3 or greater acute or late radiotherapy-related side effects. There was no radiotherapy-related vision loss or optic neuropathy. No patients required intervention or treatment replanning due to tumor changes during radiotherapy. Two patients experienced transient cyst expansion at their first post-radiotherapy MRI. Both patients were followed closely clinically and radiographically and had subsequent dramatic tumor/cyst regression, requiring no interventions. CONCLUSIONS: Our data support the safety and efficacy of proton therapy in the treatment of adult craniopharyngioma as part of primary or salvage treatment. We recommend early consideration of radiotherapy. This trial was registered at www.clinicaltrials.gov as #NCT03224767.
Authors: Quoc T Luu; Lilia N Loredo; John O Archambeau; Les T Yonemoto; James M Slater; Jerry D Slater Journal: Cancer J Date: 2006 Mar-Apr Impact factor: 3.360
Authors: Karen M Winkfield; Claudia Linsenmeier; Torunn I Yock; P Ellen Grant; Beow Y Yeap; William E Butler; Nancy J Tarbell Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-01 Impact factor: 7.038
Authors: Semi B Harrabi; Sebastian Adeberg; Thomas Welzel; Stefan Rieken; Daniel Habermehl; Jürgen Debus; Stephanie E Combs Journal: Radiat Oncol Date: 2014-09-16 Impact factor: 3.481
Authors: Michael S Rutenberg; Adam L Holtzman; Daniel J Indelicato; Soon Huh; Dinesh Rao; Peter J Fiester; Christopher G Morris; Daryoush Tavanaiepour; Robert J Amdur Journal: J Neurooncol Date: 2022-03-12 Impact factor: 4.130